Renan Ozyerli, MD, MSD Turkey
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD entered the Turkish pharma market in 1989 and established a subsidiary in 1993.
The headquarters are based in Istanbul. MSD employs 463 people in Human Health, as well as 32 people in Animal Health. Products are sourced from the global MSD network and toll manufacturing from 4 local companies. The subsidiary has a fully operational warehouse.
Currently, MSD Turkey is participating in 23 international clinical trials at 113 study centers. As such, the affiliate ranks among the top 3 research-based pharma companies in terms of clinical research capability. MSD Turkey also houses the management oversight/responsibility of Middle East and Egypt with 6 trials and 21 study centers in 5 different countries. In 2014, Merck HQ funded TRY 20.7 million (USD 9.5 million) to Turkey for clinical trials.
Contact Details
Merck Sharp Dohme İlaçları Ltd. Şti.
Esentepe Mah. Büyükdere Cad. No: 199
Levent 199 Ofis Bloğu Kat: 13, 34394 Levent-İstanbul
Tel:+90 212 336 1000
Fax:+90 212 215 2733
http://www.msd.com.tr/
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
PharmaBoardroom talked to Sr. Managing Director of Medtronic Turkey, Ayhan Ozturk about improving patient outcomes, how the company introduced a whole new standard on integrated healthcare, and their recent USD $25 million…
Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also…
Sevi Firat, Founding Partner of Firat Izgi discusses the legal challenges facing pharmaceutical companies looking to penetrate the healthcare market in Turkey, the evolution of the legal landscape and her…
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
A founding partner of YükselKarkınKüçük, Gökhan Gökçe discusses the firm’s involvement with several high profile cases concerning the healthcare and life science sector’s reference pricing system, and also elaborates on…
The managing director of DHL Express Turkey, Markus Reckling highlights the strategic importance of Turkey to the global DHL Express portfolio and elaborates on the market opportunities present for DHL’s…
The co-founder of Ekin Kimya discusses the need for greater regulation and monitoring of raw materials used in Turkish pharmaceutical manufacturing, his company’s key role as an educator and advisor…
Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived…
The chairman and CEO of Santa Farma discusses how the Turkish pharmaceutical landscape has evolved in response to the government’s healthcare transformation programs. He also enumerates various strategic initiatives the…
Omega CRO has evolved from its beginnings as a CRO contracted by local and multinational pharmaceutical companies into an organization leading clinical, epidemiological and observational studies of public interest across…
The president of the Turkish Drug and Medical Device Agency (TITCK) discusses new initiatives and reforms being carried out by his agency, including its work towards becoming a PIC/s member, and…
The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than…
See our Cookie Privacy Policy Here